Want to see RNA full AI Analyst Report?
Top Page
Atrium Therapeutics, Inc.
(NASDAQ:RNA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$8.00
▼(-41.35% Downside)
Action:Reiterated
Date:09/10/26
Overall score is held down primarily by weak financial performance (large losses and persistent cash burn) and a bearish trend indicated by price trading below key moving averages. Valuation contributes only modestly because the negative P/E reflects unprofitability and there is no dividend yield data to offset risk.
Positive Factors
Very Low Leverage
Very low leverage reduces refinancing and solvency pressure, preserving more financial flexibility than a similarly loss-making company with substantial debt. This gives Atrium greater room to manage funding needs and allocate capital while it works through its ongoing investment phase.
Negative Factors
Persistent Cash Burn
Persistent operating and free-cash-flow deficits indicate that the business is not internally funding its activities and remains reliant on external funding. This can pressure future capital allocation, increase dilution or financing needs, and limit resilience if losses continue over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Very low leverage reduces refinancing and solvency pressure, preserving more financial flexibility than a similarly loss-making company with substantial debt. This gives Atrium greater room to manage funding needs and allocate capital while it works through its ongoing investment phase.
Read all positive factors
Atrium Therapeutics, Inc. (RNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$178.21M
Dividend YieldN/A
Average Volume (3M)348.54K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees511
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,276,028
10 Day Avg. Volume239,916
30 Day Avg. Volume348,542
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)13.56
P/FCF Ratio-5.93
Enterprise Value/Market Cap-0.18
Enterprise Value/Revenue-0.90
Enterprise Value/Gross Profit-0.91
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$22.50Price Target Upside64.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atrium Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently...
Atrium Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.97M | 18.62M | 10.90M | 9.56M | 9.22M | 9.33M |
| Gross Profit | 35.48M | 18.62M | 10.90M | 7.46M | 7.84M | -91.86M |
| EBITDA | -260.06M | -76.50M | -376.16M | -233.50M | -177.53M | -117.41M |
| Net Income | -259.33M | -76.68M | -322.30M | -212.22M | -174.00M | -118.01M |
Balance Sheet | ||||||
| Total Assets | 280.51M | 278.35M | 1.56B | 628.55M | 638.80M | 427.58M |
| Cash, Cash Equivalents and Short-Term Investments | 264.21M | 270.00M | 1.50B | 595.35M | 610.73M | 405.54M |
| Total Debt | 1.68M | 3.67M | 6.80M | 9.85M | 10.69M | 11.73M |
| Total Liabilities | 65.94M | 71.07M | 138.94M | 127.79M | 60.73M | 46.15M |
| Stockholders Equity | 214.58M | 207.29M | 1.42B | 500.76M | 578.08M | 381.43M |
Cash Flow | ||||||
| Free Cash Flow | -217.39M | -42.57M | -307.94M | -123.29M | -139.09M | -98.55M |
| Operating Cash Flow | -210.49M | -41.13M | -300.87M | -119.06M | -136.27M | -94.81M |
| Investing Cash Flow | -782.49M | -1.45M | -854.20M | -130.07M | -189.96M | -82.52M |
| Financing Cash Flow | 1.17B | 42.57M | 1.19B | 93.86M | 346.17M | 176.32M |
Atrium Therapeutics, Inc. Risk Analysis
Atrium Therapeutics, Inc. disclosed 92 risk factors in its most recent earnings report. Atrium Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atrium Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $312.09M | -3.32 | -46.54% | 1.29% | -82.95% | -49.04% | |
45 Neutral | $178.21M | -2.08 | -42.90% | ― | ― | ― | |
45 Neutral | $256.87M | -13.75 | -5.76% | ― | ― | 93.45% | |
44 Neutral | $193.48M | -1.08 | 141.41% | ― | ― | ― | |
44 Neutral | $181.06M | -1.17 | -57.61% | ― | -94.10% | -122.58% | |
43 Neutral | $181.07M | -2.41 | -91.60% | ― | 3472.96% | 67.74% |
* General Sector Average
RNA
Atrium Therapeutics, Inc.
8.16
-6.59
-44.68%
ARCT
Arcturus Therapeutics
10.73
-1.27
-10.58%
RCKT
Rocket Pharmaceuticals
2.31
-1.43
-38.24%
RNAC
Cartesian Therapeutics
6.41
-2.59
-28.78%
DTIL
Precision BioSciences
6.78
-0.15
-2.16%
TRDA
Entrada Therapeutics Inc
4.73
-1.67
-26.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.